Nigella A, also named Sieboldianoside A, has been extracted from many kinds of Traditional Chinese Medicine (TCM), such as Nigella glandulifera, Stauntonia chinensis DC., and the leaves of Acanthopanax sieboldianus. Nigella A exhibited potential analgesic, anti-inflammatory, anti-tumor, and antioxidant activities. However, whether Nigella A could treat ulcerative colitis (UC) is still unknown. As saponins always be regarded as the kinds of ingredients that could regulate immunity and intestinal flora. This research aimed to investigate the therapeutic effect of Nigella A on UC and explore its effect on intestinal flora. We noted that Nigella A and Sulfasalazine (SASP) could significantly improve the signs and symptoms, alleviate colonic pathological injury in DSS-induced mice. The changing of many specific bacterial genus such as Lactobacillus, Porphyromonadaceae, Bacteroides and Escherichia might closely related to the recovery of intestinal inflammatory response. This study initially confirmed the therapeutic effect of Nigella A and SASP on DSS-induced colitis by improving the diversity of intestinal microbial composition. Nigella A has the potential to be developed for the treatment of UC and other disorders related to the imbalance of intestinal flora.

Nigella A，也称为Sieboldianoside A，已从多种中药（TCM）中提取，如Nigella glandulifera，Stauntonia chinensis DC。和Acanthopanax sieboldianus的叶子。。Nigella A表现出潜在的止痛，抗炎，抗肿瘤和抗氧化活性。但是，黑曲霉A是否可以治疗溃疡性结肠炎（UC）仍然未知。皂苷一直被视为可以调节免疫力和肠道菌群的成分。这项研究旨在调查Nigella A对UC的治疗作用，并探讨其对肠道菌群的影响。我们注意到，Nigella A和柳氮磺吡啶（SASP）可以显着改善体征和症状，减轻DSS诱导的小鼠的结肠病理损伤。许多特定细菌属的变化，如乳酸杆菌，卟啉单胞菌科，拟杆菌属和大肠埃希氏菌可能与肠道炎症反应的恢复密切相关。这项研究最初通过改善肠道微生物组成的多样性，证实了Nigella A和SASP对DSS诱导的结肠炎的治疗作用。Nigella A有潜力开发用于治疗UC和其他与肠道菌群失衡有关的疾病。